In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2Creceptor PET radioligand in nonhuman primate

10Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We recently reported the radiosynthesis and in vitro evaluation of [18F]-2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-(2-fluoroethoxy)benzyl)ethanamine, ([18F]FECIMBI-36) or ([18F]1), an agonist radioligand for 5HT2A/2Creceptors in postmortem samples of human brain. Herein we describe the in vivo evaluation of [18F]FECIMBI-36 in vervet/African green monkeys by PET imaging. PET images show that [18F]FECIMBI-36 penetrates the blood-brain barrier and a low retention of radioactivity is observed in monkey brain. Although the time activity curves indicate a somehow heterogeneous distribution of the radioligand in the brain, the low level of [18F]FECIMBI-36 in brain may limit the use of this tracer for quantification of 5-HT2A/2Creceptors by PET.

Author supplied keywords

Cite

CITATION STYLE

APA

Prabhakaran, J., Solingapuram Sai, K. K., Zanderigo, F., Rubin-Falcone, H., Jorgensen, M. J., Kaplan, J. R., … Kumar, J. S. D. (2017). In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2Creceptor PET radioligand in nonhuman primate. Bioorganic and Medicinal Chemistry Letters, 27(1), 21–23. https://doi.org/10.1016/j.bmcl.2016.11.043

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free